Biogen Idec/Elan Resubmit Tysabri With New Risk Management Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The multiple sclerosis therapy, which was withdrawn for safety reasons in February, could return to the market by late March 2006.
You may also be interested in...
FDA Clears Tysabri For Limited Clinical Use
Patients who had previously been receiving the multiple sclerosis therapy are now eligible to participate in Biogen Idec/Elan’s pending safety extension study.
FDA Clears Tysabri For Limited Clinical Use
Patients who had previously been receiving the multiple sclerosis therapy are now eligible to participate in Biogen Idec/Elan’s pending safety extension study.
Tysabri To Go Before Advisory Committee On March 7
Committee discussion will include multiple sclerosis therapy’s proposed risk management plan and possible return to market.